Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bone1 (58) 58
humans (58) 58
index medicus (58) 58
oncology (56) 56
original reports (52) 52
female (51) 51
male (51) 51
middle aged (47) 47
adult (44) 44
aged (39) 39
treatment outcome (31) 31
young adult (25) 25
adolescent (23) 23
bone2 (22) 22
bone-marrow-transplantation (20) 20
transplantation, homologous (20) 20
child (15) 15
hematopoietic stem cell transplantation (14) 14
survival analysis (14) 14
acute myeloid-leukemia (13) 13
disease-free survival (13) 13
hematopoietic stem cell transplantation - adverse effects (13) 13
prognosis (13) 13
retrospective studies (13) 13
child, preschool (12) 12
bone5 (11) 11
kaplan-meier estimate (11) 11
unrelated donors (11) 11
versus-host-disease (11) 11
acute myelogenous leukemia (10) 10
aged, 80 and over (10) 10
hematopoietic stem cell transplantation - methods (10) 10
risk factors (10) 10
survival rate (10) 10
transplantation conditioning - methods (10) 10
cohort studies (9) 9
remission induction (9) 9
stem-cell transplantation (9) 9
age factors (8) 8
graft vs host disease - prevention & control (8) 8
hematologic malignancies (8) 8
proportional hazards models (8) 8
risk assessment (8) 8
survival (8) 8
time factors (8) 8
transplantation conditioning (8) 8
cancer (7) 7
disease progression (7) 7
graft vs host disease - etiology (7) 7
hema5 (7) 7
hematologic neoplasms - therapy (7) 7
multivariate analysis (7) 7
recurrence (7) 7
bone4 (6) 6
disease (6) 6
follow-up studies (6) 6
graft vs host disease - diagnosis (6) 6
hema7 (6) 6
leukemia, myeloid, acute - surgery (6) 6
to19 (6) 6
bios4 (5) 5
bone-marrow (5) 5
hema9 (5) 5
infant (5) 5
leukemia, myeloid, acute - mortality (5) 5
leukemia, myeloid, acute - therapy (5) 5
myelodysplastic syndrome (5) 5
myelodysplastic syndromes - therapy (5) 5
neoplasm staging (5) 5
precursor cell lymphoblastic leukemia-lymphoma - mortality (5) 5
psc12 (5) 5
survivors (5) 5
tissue donors (5) 5
total-body irradiation (5) 5
bios3 (4) 4
cmpl4 (4) 4
drug administration schedule (4) 4
graft vs host disease - mortality (4) 4
hematologic neoplasms - mortality (4) 4
hematopoietic stem cell transplantation - mortality (4) 4
impact (4) 4
mutation (4) 4
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (4) 4
precursor cell lymphoblastic leukemia-lymphoma - surgery (4) 4
prospective studies (4) 4
psc13 (4) 4
response criteria (4) 4
risk-factors (4) 4
severity of illness index (4) 4
t-cells (4) 4
therapy (4) 4
to2 (4) 4
to6 (4) 4
umbilical-cord blood (4) 4
united states (4) 4
1st complete remission (3) 3
acute disease (3) 3
analysis of variance (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: Time to move toward a minimal residual disease-based definition of complete remission?
by Araki, Daisuke and Wood, Brent L and Othus, Megan and Radich, Jerald P and Halpern, Anna B and Zhou, Yi and Mielcarek, Marco and Estey, Elihu H and Appelbaum, Frederick R and Walter, Roland B
Journal of Clinical Oncology, ISSN 0732-183X, 02/2016, Volume 34, Issue 4, pp. 329 - 336
Patients with acute myeloid leukemia (AML) who are in morphologic complete remission are typically considered separately from patients with active disease (ie,... 
Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Treatment Outcome | Remission Induction | Transplantation, Homologous | Neoplasm, Residual | Young Adult | Adult | Female | Aged | Retrospective Studies | Leukemia, Myeloid, Acute - therapy | Index Medicus | ORIGINAL REPORTS | Bone1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation
by Bejar, Rafael and Stevenson, Kristen E and Caughey, Bennett and Lindsley, R. Coleman and Mar, Brenton G and Stojanov, Petar and Getz, Gad and Steensma, David P and Ritz, Jerome and Soiffer, Robert and Antin, Joseph H and Alyea, Edwin and Armand, Philippe and Ho, Vincent and Koreth, John and Neuberg, Donna and Cutler, Corey S and Ebert, Benjamin L
Journal of Clinical Oncology, ISSN 0732-183X, 09/2014, Volume 32, Issue 25, pp. 2691 - 2698
Purpose Recurrently mutated genes in myelodysplastic syndrome (MDS) are pathogenic drivers and powerfully associated with clinical phenotype and prognosis.... 
POINT MUTATIONS | PROGNOSTIC SCORING SYSTEM | IMPACT | GENE | ONCOLOGY | CLASSIFICATION | U2AF1 | TP53 MUTATIONS | DNMT3A MUTATIONS | MDS | Prognosis | Humans | Middle Aged | Male | Transplantation, Autologous | Treatment Outcome | Young Adult | Disease-Free Survival | Myelodysplastic Syndromes - therapy | Adult | Female | Aged | Myelodysplastic Syndromes - genetics | Hematopoietic Stem Cell Transplantation - methods | Mutation | Transplantation Conditioning | Index Medicus | To19 | To2 | To13 | Bone1 | To8 | ORIGINAL REPORTS | Hema9
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease
by Brudno, Jennifer N and Somerville, Robert P.T and Shi, Victoria and Rose, Jeremy J and Halverson, David C and Fowler, Daniel H and Gea-Banacloche, Juan C and Pavletic, Steven Z and Hickstein, Dennis D and Lu, Tangying L and Feldman, Steven A and Iwamoto, Alexander T and Kurlander, Roger and Maric, Irina and Goy, Andre and Hansen, Brenna G and Wilder, Jennifer S and Blacklock-Schuver, Bazetta and Hakim, Frances T and Rosenberg, Steven A and Gress, Ronald E and Kochenderfer, James N
Journal of Clinical Oncology, ISSN 0732-183X, 04/2016, Volume 34, Issue 10, pp. 1112 - 1121
Progressive malignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies... 
Leukemia, Lymphocytic, Chronic, B-Cell - surgery | Receptors, Antigen, T-Cell - metabolism | Humans | Middle Aged | Male | Remission Induction | Transplantation Chimera | Disease Progression | T-Lymphocytes - transplantation | Transplantation, Homologous | Leukemia, B-Cell - surgery | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | T-Lymphocytes - immunology | Aged | Leukemia, B-Cell - immunology | Graft vs Host Disease - etiology | Leukemia, Lymphocytic, Chronic, B-Cell - immunology | Antigens, CD19 - immunology | Index Medicus | Hema7 | Bone2 | Hema15 | To6 | Bone1 | ORIGINAL REPORTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Comorbidity-age index: A clinical measure of biologic age before allogeneic hematopoietic cell transplantation
by Sorror, Mohamed L and Storb, Rainer F and Sandmaier, Brenda M and Maziarz, Richard T and Pulsipher, Michael A and Maris, Michael B and Bhatia, Smita and Ostronoff, Fabiana and Deeg, H. Joachim and Syrjala, Karen L and Estey, Elihu and Maloney, David G and Appelbaum, Frederick R and Martin, Paul J and Storer, Barry E
Journal of Clinical Oncology, ISSN 0732-183X, 10/2014, Volume 32, Issue 29, pp. 3249 - 3256
Purpose Age has long been used as a major factor for assessing suitability for allogeneic hematopoietic cell transplantation (HCT). The HCT-comorbidity index... 
ADVANCED HEMATOLOGIC MALIGNANCIES | OLDER PATIENTS | ONCOLOGY | DONOR | BONE-MARROW-TRANSPLANTATION | DISEASE | CLASSIFICATION | ACUTE MYELOID-LEUKEMIA | UMBILICAL-CORD BLOOD | RISK-ASSESSMENT | MYELODYSPLASTIC SYNDROMES | Decision Making | Hematologic Neoplasms - therapy | Prognosis | Age Factors | Comorbidity | Health Status Indicators | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Treatment Outcome | Transplantation, Homologous | Adult | Female | Aged | Retrospective Studies | Index Medicus | Bone2 | Bone1 | Psc12 | ORIGINAL REPORTS | Bone5
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation
by John R. Wingard and Navneet S. Majhail and Ruta Brazauskas and Zhiwei Wang and Kathleen A. Sobocinski and David Jacobsohn and Mohamed L. Sorror and Mary M. Horowitz and Brian Bolwell and J. Douglas Rizzo and Gérard Socié
Journal of Clinical Oncology, ISSN 0732-183X, 06/2011, Volume 29, Issue 16, pp. 2230 - 2239
Purpose Allogeneic hematopoietic cell transplantation (HCT) is curative but is associated with life-threatening complications. Most deaths occur within the... 
2-YEAR SURVIVORS | CHILDHOOD-CANCER | SOLID CANCERS | RISK-FACTORS | ONCOLOGY | BONE-MARROW-TRANSPLANTATION | 5-YEAR SURVIVORS | ACUTE MYELOID-LEUKEMIA | LATE MORTALITY | LYMPHOPROLIFERATIVE DISORDERS | FUNCTIONAL STATUS | Graft vs Host Disease - epidemiology | Age Factors | Follow-Up Studies | Humans | Middle Aged | Risk Factors | Child, Preschool | Hematologic Diseases - surgery | Infant | Male | Hematopoietic Stem Cell Transplantation - mortality | Cause of Death | Transplantation, Homologous | Young Adult | Adolescent | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Aged | Child | Index Medicus | Bone2 | Original Reports | Bone1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
by Stephen P. Hunger and Xiaomin Lu and Meenakshi Devidas and Bruce M. Camitta and Paul S. Gaynon and Naomi J. Winick and Gregory H. Reaman and William L. Carroll
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 14, pp. 1663 - 1669
Purpose To examine population-based improvements in survival and the impact of clinical covariates on outcome among children and adolescents with acute... 
YOUNG-ADULTS | CANCER CLINICAL-TRIALS | PROGNOSTIC-FACTORS | GENE | ONCOLOGY | INFANTS | STEM-CELL TRANSPLANTATION | MINIMAL RESIDUAL DISEASE | EXPRESSION | B-PROGENITOR | RISK CLASSIFICATION | Multivariate Analysis | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Age Factors | United States | Humans | Child, Preschool | National Cancer Institute (U.S.) | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Cause of Death | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Time Factors | Female | Retrospective Studies | Child | Severity of Illness Index | Risk Assessment | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Clinical Trials as Topic | Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis | Disease Progression | Disease-Free Survival | Adolescent | Sex Factors | Survival Analysis | Cohort Studies | Index Medicus | Adolescence | Acute lymphatic leukemia | Cell survival | Risk groups | Toxicity | Clinical trials | Oncology | Infants | Lymphocytes T | Survival | Races | Lymphocytes B | Ethnic groups | Children | Age | ORIGINAL REPORTS | Bone4 | Bone1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
by Robyn M. Emanuel and Amylou C. Dueck and Holly L. Geyer and Jean-Jacques Kiladjian and Stefanie Slot and Sonja Zweegman and Peter A.W. te Boekhorst and Suzan Commandeur and Harry C. Schouten and Federico Sackmann and Ana Kerguelen Fuentes and Dolores Hernández-Maraver and Heike L. Pahl and Martin Griesshammer and Frank Stegelmann and Konstanze Doehner and Thomas Lehmann and Karin Bonatz and Andreas Reiter and Francoise Boyer and Gabriel Etienne and Jean-Christophe Ianotto and Dana Ranta and Lydia Roy and Jean-Yves Cahn and Claire N. Harrison and Deepti Radia and Pablo Muxi and Norman Maldonado and Carlos Besses and Francisco Cervantes and Peter L. Johansson and Tiziano Barbui and Giovanni Barosi and Alessandro M. Vannucchi and Francesco Passamonti and Bjorn Andreasson and Maria L. Ferarri and Alessandro Rambaldi and Jan Samuelsson and Gunnar Birgegard and Ayalew Tefferi and Ruben A. Mesa and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Institutionen för medicinska vetenskaper and Hematologi
Journal of Clinical Oncology, ISSN 0732-183X, 11/2012, Volume 30, Issue 33, pp. 4098 - 4103
textabstractPurpose: Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment... 
MYELOFIBROSIS | TRIAL | QUALITY-OF-LIFE | INVENTORY | ONCOLOGY | FATIGUE | Myeloproliferative Disorders - diagnosis | Severity of Illness Index | Prospective Studies | Sickness Impact Profile | Humans | Middle Aged | Male | Myeloproliferative Disorders - pathology | Young Adult | Aged, 80 and over | Quality of Life | Adult | Female | Surveys and Questionnaires | Aged | Index Medicus | Myeloproliferative Disorders | Life Sciences | Questionnaires | Cancer | Hema6 | Psc5 | Bone1 | Hema4 | ORIGINAL REPORTS | Pedi3 | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome
by Brian L. McClune and Daniel J. Weisdorf and Tanya L. Pedersen and Gisela Tunes da Silva and Martin S. Tallman and Jorge Sierra and John DiPersio and Armand Keating and Robert P. Gale and Biju George and Vikas Gupta and Theresa Hahn and Luis Isola and Madan Jagasia and Hillard Lazarus and David Marks and Richard Maziarz and Edmund K. Waller and Chris Bredeson and Sergio Giralt
Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 11, pp. 1878 - 1887
Purpose Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) primarily afflict older individuals. Hematopoietic cell transplantation (HCT) is... 
SURVIVAL | GRAFT-VERSUS-MALIGNANCY | SOUTHWEST-ONCOLOGY-GROUP | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | UNRELATED DONORS | HOST-DISEASE | MARROW-TRANSPLANTATION | CONDITIONING REGIMENS | HEMATOLOGIC MALIGNANCIES | ELDERLY-PATIENTS | Age Factors | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Neoplasm Recurrence, Local - therapy | Hematopoietic Stem Cell Transplantation | Male | Survival Rate | Treatment Outcome | Remission Induction | Transplantation, Homologous | Neoplasm Recurrence, Local - pathology | Adult | Female | Aged | Transplantation Conditioning | Neoplasm Staging | Leukemia, Myeloid, Acute - therapy | Index Medicus | Original Reports | Bone1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
by John Koreth and Joseph Pidala and Waleska S. Perez and H. Joachim Deeg and Guillermo Garcia-Manero and Luca Malcovati and Mario Cazzola and Sophie Park and Raphael Itzykson and Lionel Ades and Pierre Fenaux and Martin Jadersten and Eva Hellstrom-Lindberg and Robert Peter Gale and C.L. Beach and Stephanie J. Lee and Mary M. Horowitz and Peter L. Greenberg and Martin S. Tallman and John F. DiPersio and Donald Bunjes and Daniel J. Weisdorf and Corey Cutler
Journal of Clinical Oncology, ISSN 0732-183X, 07/2013, Volume 31, Issue 21, pp. 2662 - 2670
Purpose Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders that are more common in patients aged >= 60 years and are incurable with... 
PROGNOSTIC SCORING SYSTEM | HODGKINS-DISEASE | MYELOPROLIFERATIVE DISORDERS | ONCOLOGY | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | HLA-IDENTICAL SIBLINGS | PHASE-III | PREDICTING SURVIVAL | ACUTE MYELOID-LEUKEMIA | LIFE EXPECTANCY | Markov Chains | Humans | Middle Aged | Decision Support Techniques | Quality of Life | Female | Male | Aged | International Cooperation | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Myelodysplastic Syndromes - surgery | Index Medicus | ORIGINAL REPORTS | Hema5 | Bone1 | Klinisk medicin | Medicin och hälsovetenskap | Kirurgi | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
by Lanlan Shen and Hagop Kantarjian and Yi Guo and E Lin and Jianqin Shan and Xuelin Huang and Donald Berry and Saira Ahmed and Wei Zhu and Sherry Pierce and Yutaka Kondo and Yasuhiro Oki and Jaroslav Jelinek and Hussain Saba and Eli Estey and Jean-Pierre J. Issa
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 4, pp. 605 - 613
Purpose The current classification systems of myelodysplastic syndromes (MDS), including the International Prognostic Scoring System (IPSS), do not fully... 
CANCER-CELLS | TRANSFORMATION | PROGNOSTIC IMPACT | HYPERMETHYLATION | GENE | ONCOLOGY | CPG ISLAND | POOR-PROGNOSIS | P15(INK4B) | ACUTE MYELOID-LEUKEMIA | DISEASE PROGRESSION | Humans | Middle Aged | Male | Survival Rate | Treatment Outcome | Randomized Controlled Trials as Topic | Young Adult | Disease-Free Survival | Clinical Trials, Phase III as Topic | DNA Methylation | Myelodysplastic Syndromes - therapy | Multicenter Studies as Topic | Myelodysplastic Syndromes - mortality | Polymerase Chain Reaction | Aged, 80 and over | CpG Islands | Adult | Female | Aged | Myelodysplastic Syndromes - genetics | Neoplasm Staging | Cohort Studies | Index Medicus | Original Reports | Bios4 | Bone1 | To2 | Hema9
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
by David P. Steensma and Maria R. Baer and James L. Slack and Rena Buckstein and Lucy A. Godley and Guillermo Garcia-Manero and Maher Albitar and Julie S. Larsen and Sujata Arora and Michael T. Cullen and Hagop Kantarjian
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3842 - 3848
Purpose Decitabine, a DNA-targeted hypomethylating agent, is approved by the United States Food and Drug Administration for treatment of patients with... 
AGENT | DNA METHYLATION | RESPONSE CRITERIA | ONCOLOGY | 5-AZA-2'-DEOXYCYTIDINE DECITABINE | EXPERIENCE | LEUKEMIAS | INTERNATIONAL WORKING GROUP | Drug Administration Schedule | Humans | Middle Aged | Kaplan-Meier Estimate | Azacitidine - analogs & derivatives | Male | Treatment Outcome | Antimetabolites, Antineoplastic - administration & dosage | Outpatients | Aged, 80 and over | Adult | Female | Aged | Infusions, Intravenous | Myelodysplastic Syndromes - pathology | Myelodysplastic Syndromes - drug therapy | Azacitidine - administration & dosage | Index Medicus | Hema7 | ORIGINAL REPORTS | Bone1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
by Alfonso Quintás-Cardama and Hagop Kantarjian and Taghi Manshouri and Rajyalakshmi Luthra and Zeev Estrov and Sherry Pierce and Mary Ann Richie and Gautam Borthakur and Marina Konopleva and Jorge Cortes and Srdan Verstovsek
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 32, pp. 5418 - 5424
Purpose We conducted a phase II study of pegylated interferon alfa-2a (PEG-IFN-alpha-2a) in patients with essential thrombocythemia (ET) and polycythemia vera... 
CHRONIC MYELOGENOUS LEUKEMIA | V617F MUTATION | MYELOFIBROSIS | PROGENITORS | THERAPY | MYELOPROLIFERATIVE DISORDERS | ONCOLOGY | HYDROXYUREA | TYROSINE KINASE JAK2 | RISK | MYELOID METAPLASIA | Thrombocythemia, Essential - drug therapy | Humans | Middle Aged | Interferon-alpha - therapeutic use | Janus Kinase 2 - genetics | Polyethylene Glycols - adverse effects | Polycythemia Vera - genetics | Thrombocythemia, Essential - pathology | Treatment Outcome | Recombinant Proteins | Thrombocythemia, Essential - genetics | Polyethylene Glycols - therapeutic use | Young Adult | Adolescent | Adult | Polycythemia Vera - drug therapy | Aged | Interferon-alpha - adverse effects | Mutation | Polycythemia Vera - pathology | Neutropenia - chemically induced | Index Medicus | Hema7 | Bios3 | Bone1 | ORIGINAL REPORTS | Hema9
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning
by Kanakry, Christopher G and O'Donnell, Paul V and Furlong, Terry and De Lima, Marcos J and Wei, Wei and Medeot, Marta and Mielcarek, Marco and Champlin, Richard E and Jones, Richard J and Thall, Peter F and Andersson, Borje S and Luznik, Leo
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 31, pp. 3497 - 3505
Purpose The clinical safety and efficacy of intravenous busulfan and fludarabine (IV Bu/Flu) myeloablative conditioning as well as graft-versus-host disease... 
PLUS CYCLOPHOSPHAMIDE | RESPONSE CRITERIA | ONCOLOGY | MATCHED UNRELATED DONORS | VENOOCCLUSIVE DISEASE | DAILY INTRAVENOUS BUSULFAN | PERIPHERAL-BLOOD | ACUTE MYELOID-LEUKEMIA | STEM-CELL TRANSPLANTATION | HEMATOLOGIC MALIGNANCIES | INTERNATIONAL WORKING GROUP | Myeloablative Agonists - therapeutic use | Graft vs Host Disease - epidemiology | Busulfan - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Treatment Outcome | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Cyclophosphamide - therapeutic use | Incidence | Bayes Theorem | Adult | Female | Graft vs Host Disease - prevention & control | Aged | Transplantation Conditioning - methods | Index Medicus | ORIGINAL REPORTS | Bone1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors
by Theresa Hahn and Philip L. McCarthy Jr and Anna Hassebroek and Christopher Bredeson and James L. Gajewski and Gregory A. Hale and Luis M. Isola and Hillard M. Lazarus and Stephanie J. Lee and Charles F. LeMaistre and Fausto Loberiza and Richard T. Maziarz and J. Douglas Rizzo and Steven Joffe and Susan Parsons and Navneet S. Majhail
Journal of Clinical Oncology, ISSN 0732-183X, 07/2013, Volume 31, Issue 19, pp. 2437 - 2449
Purpose Over the past four decades, allogeneic hematopoietic cell transplantation (alloHCT) has evolved as a curative modality for patients with hematologic... 
PROPHYLAXIS | THERAPY | ONCOLOGY | INTENSITY | MYELOID-LEUKEMIA | VERSUS-HOST-DISEASE | MYELODYSPLASTIC SYNDROME | MDS | PROGRAM | BLOOD | REGISTRY | United States - epidemiology | Age Factors | Precursor Cell Lymphoblastic Leukemia-Lymphoma - surgery | Hematologic Neoplasms - mortality | Humans | Middle Aged | Child, Preschool | Infant | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Lymphoma, Non-Hodgkin - surgery | Hodgkin Disease - surgery | Transplantation, Homologous | Canada - epidemiology | Hematopoietic Stem Cell Transplantation - utilization | Hodgkin Disease - mortality | Adult | Female | Leukemia, Myeloid, Acute - surgery | Unrelated Donors | Retrospective Studies | Child | Myelodysplastic Syndromes - surgery | SEER Program | Survival Rate | Hematologic Neoplasms - surgery | Leukemia, Myeloid, Acute - mortality | Adolescent | Myelodysplastic Syndromes - mortality | Survival Analysis | Aged | Lymphoma, Non-Hodgkin - mortality | Cohort Studies | Index Medicus | Bone2 | Bone3 | Bone1 | ORIGINAL REPORTS | Bone4 | Bone5
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation
by Rainer Storb and Boglarka Gyurkocza and Barry E. Storer and Mohamed L. Sorror and Karl Blume and Dietger Niederwieser and Thomas R. Chauncey and Michael A. Pulsipher and Finn B. Petersen and Firoozeh Sahebi and Edward D. Agura and Parameswaran Hari and Benedetto Bruno and Peter A. McSweeney and Michael B. Maris and Richard T. Maziarz and Amelia A. Langston and Wolfgang Bethge and Lars Vindeløv and Georg-Nikolaus Franke and Ginna G. Laport and Andrew M. Yeager and Kai Hübel and H. Joachim Deeg and George E. Georges and Mary E.D. Flowers and Paul J. Martin and Marco Mielcarek and Ann E. Woolfrey and David G. Maloney and Brenda M. Sandmaier
Journal of Clinical Oncology, ISSN 0732-183X, 04/2013, Volume 31, Issue 12, pp. 1530 - 1538
Purpose We designed a minimal-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic... 
TOTAL-BODY IRRADIATION | RELAPSE | BONE-MARROW TRANSPLANTATION | ONCOLOGY | MATCHED UNRELATED DONORS | IMMUNOSUPPRESSION | MYELOGENOUS LEUKEMIA | HCT | RISK | OUTCOMES | HEMATOLOGIC MALIGNANCIES | Hematologic Neoplasms - therapy | Prognosis | Follow-Up Studies | Hematologic Neoplasms - mortality | Humans | Middle Aged | Child, Preschool | Infant | Male | Neoplasm Recurrence, Local - mortality | Transplantation, Homologous | Young Adult | Graft vs Host Disease - mortality | Graft Rejection - mortality | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Hematologic Neoplasms - complications | Child | Graft vs Host Disease - etiology | Infant, Newborn | Graft Rejection - etiology | Graft vs Tumor Effect | Survival Rate | Combined Modality Therapy | Neoplasm Recurrence, Local - diagnosis | HLA Antigens - metabolism | Adolescent | Aged | Transplantation Conditioning | Neoplasm Staging | Index Medicus | Bone2 | Original Reports | Bone1 | Bone5
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure
by Michel Duval and John P. Klein and Wensheng He and Jean-Yves Cahn and Mitchell Cairo and Bruce M. Camitta and Rammurti Kamble and Edward Copelan and Marcos de Lima and Vikas Gupta and Armand Keating and Hillard M. Lazarus and Mark R. Litzow and David I. Marks and Richard T. Maziarz and David A. Rizzieri and Gary Schiller and Kirk R. Schultz and Martin S. Tallman and Daniel Weisdorf
Journal of Clinical Oncology, ISSN 0732-183X, 08/2010, Volume 28, Issue 23, pp. 3730 - 3738
Purpose Patients with acute leukemia refractory to induction or reinduction chemotherapy have poor prognoses if they do not undergo hematopoietic stem-cell... 
TOTAL-BODY IRRADIATION | SURVIVAL | CORD BLOOD TRANSPLANTATION | ONCOLOGY